Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Evusheld safety checked in japanese patients

NCT ID NCT05687877

First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 25 times

Summary

This study tracked 366 people in Japan who received Evusheld to treat or prevent COVID-19. The goal was to see what side effects occurred in real-world use. The study focused on serious allergic reactions and heart problems. Results help doctors understand the drug's safety profile.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Aichi, Japan

  • Research Site

    Chiba, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Fukushima, Japan

  • Research Site

    Hiroshima, Japan

  • Research Site

    Hokkaido, Japan

  • Research Site

    Hyōgo, Japan

  • Research Site

    Ibaraki, Japan

  • Research Site

    Ishikawa, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Kanagawa, Japan

  • Research Site

    Kyoto, Japan

  • Research Site

    Mie, Japan

  • Research Site

    Nara, Japan

  • Research Site

    Numakunai, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Tottori, Japan

Conditions

Explore the condition pages connected to this study.